Table.
Laboratory Tests at the Time of Rituximab Administration.
| <Complete blood cell counts> | <Chemical analysis> | <Urinalysis> | ||||||
| WBC | 6,370 | /µL | Total protein | 5.6 | g/dL | Protein | 3+ | |
| Neutrophils | 80.9 | % | Albumin | 3.5 | g/dL | Occult blood | 3+ | |
| Lymphocytes | 6.0 | % | Blood urea nitrogen | 65.4 | mg/dL | RBCs | 30-49 | /HPF |
| Monocytes | 10.8 | % | Creatinine | 3.39 | mg/dL | Protein | 7.60 | g/gCr |
| Eosinophils | 2.0 | % | eGFR | 10.7 | mL/min/1.73 m2 | epithelium casts | 10-19 | /WF |
| Hb | 8.5 | g/dL | AST | 18 | IU/L | granular casts | 5-9 | /HPF |
| MCV | 89.3 | fL | ALT | 19 | IU/L | RBC-cast | 1-4 | /WF |
| Platelets | 212,000 | /µL | Na | 138 | mmol/L | |||
| <Serological test> | K | 5.5 | mmol/L | |||||
| IgG | 628.0 | mg/dL | Cl | 106 | mmol/L | |||
| MPO-ANCA | 274 | IU/mL | Ca | 8.0 | mg/dL | |||
| PR3-ANCA | negative | P | 4.7 | mg/dL | ||||
| Anti-GBM antibody | negative | CRP | 0.77 | mg/dL | ||||
| HBs antigen | 0.00 | IU/mL | ||||||
| HBs antibody | >1,000.0 | mIU/mL | ||||||
| HBc antibody | 8.21 | S/CO | ||||||
| HBV-DNA | negative | |||||||
MCV: mean corpuscular volume, MPO-ANCA: myeloperoxidase-antineutrophil cytoplasmic antibodies, PR3-ANCA: proteinase-3-anti-neutrophil cytoplasmic antibodies, GBM: glomerular basement membrane, HBs: hepatitis B surface, HBc: hepatitis B core, S/CO: Sample RLU/cut-off, HBV: hepatitis B virus, eGFR: estimated glomerular filtration rate, AST: asparatate aminotransferase, ALT: alanine aminotransferase, CRP: C-reactive protein, RBCs: red blood cells